• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Investigation of chitosan-g-PEG grafted nanoparticles as a half-life enhancer carrier for tissue plasminogen activator delivery.壳聚糖-g-PEG 接枝纳米粒作为组织型纤溶酶原激活物给药半衰期增强载体的研究。
IET Nanobiotechnol. 2020 Dec;14(9):899-907. doi: 10.1049/iet-nbt.2019.0304.
2
Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme.制备聚乙二醇接枝壳聚糖/链激酶纳米粒以提高酶的生物半衰期并降低其免疫原性。
Int J Biol Macromol. 2020 Jan 15;143:181-189. doi: 10.1016/j.ijbiomac.2019.11.157. Epub 2019 Nov 20.
3
The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.聚乙二醇化脂质体用于延长组织型纤溶酶原激活剂的循环寿命。
Biomaterials. 2009 Oct;30(29):5751-6. doi: 10.1016/j.biomaterials.2009.07.021. Epub 2009 Aug 4.
4
Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.血栓靶向纳米载体可减轻与常规溶栓治疗相关的出血并发症。
Pharm Res. 2013 Jun;30(6):1663-76. doi: 10.1007/s11095-013-1011-x. Epub 2013 Mar 7.
5
Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction.壳聚糖和聚乙二醇修饰壳聚糖纳米粒共包封白藜芦醇和槲皮素:用于有效降低眼内压。
Int J Biol Macromol. 2017 Nov;104(Pt B):1837-1845. doi: 10.1016/j.ijbiomac.2017.04.117. Epub 2017 May 1.
6
Development of Octreotide-Loaded Chitosan and Heparin Nanoparticles: Evaluation of Surface Modification Effect on Physicochemical Properties and Macrophage Uptake.奥曲肽载壳聚糖和肝素纳米粒的研制:表面修饰对理化性质和巨噬细胞摄取的影响评价。
J Pharm Sci. 2019 Sep;108(9):3036-3045. doi: 10.1016/j.xphs.2019.05.002. Epub 2019 May 10.
7
Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.以组织型纤溶酶原激活剂肽为靶向部分的蛋白酶激活纳米颗粒的合成、功能化及其作为胰腺癌诊断工具的研究
J Nanobiotechnology. 2016 Dec 19;14(1):81. doi: 10.1186/s12951-016-0236-3.
8
Encapsulation and release of plasminogen activator from biodegradable magnetic microcarriers.纤溶酶原激活剂从可生物降解磁性微载体中的包封与释放
Eur J Pharm Sci. 2008 Sep 2;35(1-2):96-103. doi: 10.1016/j.ejps.2008.06.012. Epub 2008 Jul 3.
9
Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats.采用聚乙二醇接枝壳聚糖纳米粒提高虾青素的肠道吸收和口服生物利用度:制备、体外评价及在大鼠体内的药代动力学。
J Sci Food Agric. 2022 Feb;102(3):1002-1011. doi: 10.1002/jsfa.11435. Epub 2021 Aug 13.
10
Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.用包裹在聚(丙交酯-乙交酯)(PLGA)纳米颗粒中的壳聚糖包被纤溶酶原激活剂加速溶栓
Biomaterials. 2008 Jan;29(2):228-37. doi: 10.1016/j.biomaterials.2007.09.027. Epub 2007 Oct 22.

本文引用的文献

1
Recent advances in polymeric drug delivery systems.聚合物药物递送系统的最新进展。
Biomater Res. 2020 Jun 6;24:12. doi: 10.1186/s40824-020-00190-7. eCollection 2020.
2
Engineered microparticles and nanoparticles for fibrinolysis.用于纤维蛋白溶解的工程化微球和纳米颗粒。
J Thromb Haemost. 2019 Dec;17(12):2004-2015. doi: 10.1111/jth.14637. Epub 2019 Oct 7.
3
Box-Behnken Design of Experiment Assisted Development and Optimization of Bendamustine HCl loaded Hydroxyapatite Nanoparticles.实验的Box-Behnken设计辅助盐酸苯达莫司汀负载羟基磷灰石纳米颗粒的开发与优化。
Curr Drug Deliv. 2018;15(9):1230-1244. doi: 10.2174/1567201815666180620123347.
4
Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines?壳聚糖作为抗结核疫苗佐剂/递药系统合适吗?
Microb Pathog. 2018 Aug;121:218-223. doi: 10.1016/j.micpath.2018.05.035. Epub 2018 May 23.
5
Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design.新型辛酰化壳聚糖纳米粒的研制及其对利福平肺部递药的改善:通过析因设计进行优化。
AAPS PharmSciTech. 2018 May;19(4):1758-1772. doi: 10.1208/s12249-018-0972-9. Epub 2018 Mar 27.
6
Parameters influencing the size of chitosan-TPP nano- and microparticles.影响壳聚糖-三聚磷酸钠纳米和微粒尺寸的参数。
Sci Rep. 2018 Mar 16;8(1):4695. doi: 10.1038/s41598-018-23064-4.
7
The cartilage-specific lectin C-type lectin domain family 3 member A (CLEC3A) enhances tissue plasminogen activator-mediated plasminogen activation.软骨特异性凝集素 C 型凝集素结构域家族 3 成员 A(CLEC3A)增强组织型纤溶酶原激活物介导的纤溶酶原激活。
J Biol Chem. 2018 Jan 5;293(1):203-214. doi: 10.1074/jbc.M117.818930. Epub 2017 Nov 16.
8
Stroke Death Rate Plateaus.中风死亡率趋于平稳。
JAMA. 2017 Nov 14;318(18):1751. doi: 10.1001/jama.2017.15453.
9
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.基于组织型纤溶酶原激活物的纳米溶栓治疗缺血性脑卒中。
Expert Opin Drug Deliv. 2018 Feb;15(2):173-184. doi: 10.1080/17425247.2018.1384464. Epub 2017 Sep 28.
10
Synthesis and Characterization of Tissue Plasminogen Activator-Functionalized Superparamagnetic Iron Oxide Nanoparticles for Targeted Fibrin Clot Dissolution.用于靶向纤维蛋白凝块溶解的组织型纤溶酶原激活剂功能化超顺磁性氧化铁纳米颗粒的合成与表征
Int J Mol Sci. 2017 Aug 24;18(9):1837. doi: 10.3390/ijms18091837.

壳聚糖-g-PEG 接枝纳米粒作为组织型纤溶酶原激活物给药半衰期增强载体的研究。

Investigation of chitosan-g-PEG grafted nanoparticles as a half-life enhancer carrier for tissue plasminogen activator delivery.

机构信息

Atherosclerosis Research Center, Baqiyatallah University of Medical Science, Tehran, Iran.

Department of Medical Nanotechnology, Applied Biophotonics Research Center, Science and Research Branch, Islamic Azad University, Tehran, Iran.

出版信息

IET Nanobiotechnol. 2020 Dec;14(9):899-907. doi: 10.1049/iet-nbt.2019.0304.

DOI:10.1049/iet-nbt.2019.0304
PMID:33399124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8676530/
Abstract

Tissue plasminogen activator (tPA) a thrombolytic agent is commonly used for digesting the blood clot. tPA half-life is low (4-6 min) and its administration needs a prolonged continuous infusion. Improving tPA half-life could reduce enzyme dosage and enhance patient compliance. Nano-carries could be used as delivery systems for the protection of enzymes physically, enhancing half-life and increasing the stability of them. In this study, chitosan (CS) and polyethylene glycol (PEG) were used for the preparation of CS-g-PEG/tPA nanoparticles (NPs) via the ion gelation method. Particles' size and loading capacity were optimised by central composite design. Then, NPs cytotoxicity, release profile, enzyme activity and in vivo half-life and coagulation time were investigated. The results showed that NPs does not have significant cytotoxicity. Release study revealed that a burst effect happened in the first 5 min and resulted in releasing 30% of tPA. Loading tPA in NPs could decrease 25% of its activity but the half-life of it increases in comparison to free tPA in vivo. Also, blood coagulation time has significantly affected (-value = 0.041) by encapsulated tPA in comparison to free tPA. So, CS-g-PEG/tPA could increase enzyme half-life during the time and could be used as a non-toxic candidate delivery system for tPA.

摘要

组织型纤溶酶原激活剂(tPA)是一种常用的溶栓药物,用于分解血凝块。tPA 的半衰期较短(4-6 分钟),需要长时间持续输注。延长 tPA 的半衰期可以减少酶的用量,提高患者的依从性。纳米载体可用作酶的保护和输送系统,通过物理方式提高半衰期并增强其稳定性。在这项研究中,壳聚糖(CS)和聚乙二醇(PEG)通过离子凝胶法用于制备 CS-g-PEG/tPA 纳米颗粒(NPs)。通过中心复合设计优化了颗粒的粒径和载药量。然后,研究了 NPs 的细胞毒性、释放特性、酶活性以及体内半衰期和凝血时间。结果表明,NPs 没有明显的细胞毒性。释放研究表明,在最初的 5 分钟内会发生爆发效应,导致 30%的 tPA 释放。将 tPA 载入 NPs 中可以降低其 25%的活性,但与游离 tPA 相比,其体内半衰期会延长。此外,凝血时间也显著影响了包载 tPA 的活性(-值=0.041)。因此,CS-g-PEG/tPA 可以在延长时间内增加酶的半衰期,并且可以作为 tPA 的一种非毒性候选输送系统。